Cellular homeostasis depends critically on the controlled degradation of proteins. Cells employ an intricate waste-disposal system to ensure that obsolete or harmful proteins are tagged for destruction and subsequently dismantled by specialized enzymes. Exploiting this natural process, molecular glues function by bridging proteins that do not normally interact, guiding harmful proteins toward degradation pathways. This elegant strategy offers an unprecedented level of selectivity and therapeutic potential, particularly for proteins that evade conventional drug targeting.

Historically, the identification of molecular glues has been serendipitous, limiting efficient exploitation across diverse therapeutic landscapes. Addressing this, a team led by Georg Winter, Scientific Director at the AITHYRA Research Institute and Adjunct Principal Investigator at CeMM in Vienna, alongside Michael Erb from the Scripps Research Institute, developed an innovative high-throughput chemical diversification technique paired with live-cell functional screening. This approach enables the rapid exploration of vast chemical modifications on an initial small molecule scaffold, uncovering variants that effectively reshape protein surfaces to foster new protein-protein interactions.

This methodology involves synthesizing thousands of molecular variants by systematically appending diverse chemical building blocks to a known protein ligand. Each variant subtly alters the ligand’s interface, potentially fostering novel contacts between the target protein and cellular degradation enzymes. Crucially, the screening is conducted in live cells without prior compound purification, using sensitive assays that report real-time degradation of the protein target. This fusion of chemical synthesis and cellular biology allows researchers to pinpoint active compounds with genuine biological efficacy from enormous chemical spaces in a highly efficient manner.

The researchers applied this cutting-edge approach to the leukemia-associated protein ENL, a critical regulator in certain aggressive forms of acute leukemia. Screening thousands of ligand derivatives led to identifying a compound that selectively induces robust degradation of ENL in leukemia cells. Subsequent investigations demonstrated that this compound reprograms the protein’s interaction landscape, promoting recruitment of a ubiquitin ligase complex responsible for tagging ENL with ubiquitin molecules, effectively marking it for destruction by the proteasome.

Fundamental to the activity of these compounds is their cooperative binding mechanism, a hallmark of molecular glues. Rather than indiscriminately binding to both partners, the molecule binds the target protein first, then facilitates a new interface that recruits the enzymatic degradation machinery. This mechanism underpins both the specificity and efficacy of the induced protein degradation, minimizing off-target effects and enhancing therapeutic potential.

The successful targeted degradation of ENL elucidates the enormous promise held by molecular glue technology. By precisely ablating proteins driving leukemia progression, this approach curtails malignant cell growth and opens pathways for new leukemia treatments with potentially fewer side effects compared to current therapies. Moreover, the demonstration that high-throughput ligand diversification and functional screening can yield such potent glues paves the way for broad applications across a spectrum of diseases.

The implications of this work extend far beyond ENL and leukemia. The generalizable workflow combining scalable chemical innovation with phenotype-based cellular screening transforms the paradigm of proximity-inducing drug discovery. Where once the hunt for molecular glues was slow and hit-or-miss, it can now be approached rationally with vast chemical libraries tested directly in biological contexts, accelerating the translation from molecule to medicine.

Georg Winter emphasizes that this breakthrough sets the foundation for a new era in drug design, making it feasible to target proteins, once deemed ‘undruggable,’ with small molecules that enlist the cell’s own degradation machinery for therapeutic benefit. This extends the druggable proteome dramatically, enabling intervention in diseases where pathogenic proteins have historically eluded pharmacological control.

Furthermore, the integration of artificial intelligence and next-generation automated chemistry platforms at institutions like AITHYRA will likely amplify this approach’s efficiency and breadth. The convergence of AI-driven design, robotic synthesis, and live-cell functional assays creates a powerful ecosystem to systematically identify molecular glues tailored to diverse therapeutic targets, accelerating drug discovery timelines significantly.

As molecular glues gain traction in both academic and pharmaceutical sectors, the strategy heralded by this study could revolutionize how diseases such as cancer, neurodegeneration, and viral infections are treated. Through rational, scalable ligand diversification paired with cell-based functional screening, there is newfound optimism that targeted protein degradation can become a mainstay of precision medicine, offering customized therapies with high specificity and minimal side effects.

This landmark study, published in Nature Chemical Biology, underscores the transformative potential of combining high-throughput chemistry with live-cell biology to unlock new drug modalities. The systematic discovery of molecular glues not only represents a technical tour de force but also a conceptual leap forward, fostering a deeper understanding of protein interactions and cellular degradation pathways that can be leveraged for therapeutic innovation.

The impact of these findings is already resonating through the scientific community, evoking excitement about the possibilities molecular glues hold for treating a vast array of diseases. As this platform matures, it promises to illuminate previously dark corners of the proteome, making the impossible task of targeting elusive proteins a tangible reality.

Subject of Research: Cells

Article Title: High-throughput ligand diversification to discover chemical inducers of proximity

News Publication Date: February 16, 2026

Web References:
https://doi.org/10.1038/s41589-025-02137-2

References:
Shaum JB, Muñoz i Ordoño M, Steen EA, et al. High-throughput ligand diversification to discover chemical inducers of proximity. Nature Chemical Biology. 2026; DOI:10.1038/s41589-025-02137-2.

Image Credits: © Miquel Muñoz

Keywords: Leukemia, Proteins, Molecular glues, Targeted protein degradation, High-throughput screening, Chemical biology, Drug discovery, Acute leukemia, Ubiquitin ligase, ENL protein

Phenotypic screening, a cornerstone in drug discovery, traditionally involves evaluating a compound library against cellular models to identify molecules inducing desired biological responses. Despite its effectiveness in revealing novel mechanisms of action, this approach is notoriously resource-intensive and time-consuming, particularly when scaled to high-throughput formats essential for comprehensive screening. Leveraging deep learning, the research team bypassed these limitations by constructing a data-driven classification-generation cascade that predicted phenotypic outcomes from chemical structures in silico. This paradigm shift not only accelerates hit identification but also reduces experimental burden and costs substantially, representing a quantum leap over conventional methods.

The model facilitated the discovery of two tetrahydrocarbazole derivatives, WJ0976 and WJ0909, which demonstrated remarkable antineoplastic properties. WJ0909, more specifically its enantiomer R-(−)-WJ0909 (designated WJ0909B), emerged as a lead candidate exhibiting optimal efficacy across diverse cancer types in vitro and ex vivo using patient-derived organoids (PDOs). The pan-cancer activity profile of these compounds, coupled with their ability to suppress growth in multidrug-resistant cell lines, underscores their potential as versatile therapeutic agents capable of overcoming common obstacles in cancer treatment, such as resistance development and tumor heterogeneity.

Mechanistic investigations into WJ0909B’s mode of action revealed that it acts by upregulating the tumor suppressor protein p53, a pivotal regulator of cell cycle and apoptosis. The enhanced expression of p53 initiated mitochondria-dependent endogenous apoptotic pathways, leading to programmed cell death selectively in cancer cells. This mechanism, distinguished by its reliance on intrinsic apoptotic signaling rather than extrinsic cues, holds promise for high specificity and minimization of systemic toxicity—a critical consideration in antitumor drug design. Moreover, activation of p53 is a strategic therapeutic target given its frequent inactivation in malignant cells, often linked to uncontrolled proliferation and survival.

Complementing its intrinsic antitumor properties, the research introduced a click chemistry-enabled prodrug variant, WJ0909B-TCO, designed for targeted cancer therapy. This innovative approach employs a bioorthogonal click-activated strategy that ensures the prodrug remains inactive systemically but undergoes rapid activation upon reaching the tumor microenvironment. Through this controlled activation, therapeutic efficacy is maximized locally while minimizing off-target effects and systemic toxicity. In vivo studies using cell-derived xenograft models confirmed the potent tumor inhibition capability of both WJ0909B and its prodrug counterpart, validating the translational potential of this targeted delivery platform.

The implications of this study extend beyond the immediate discovery of novel compounds. By demonstrating the successful application of deep learning to phenotypic screening and drug design, the researchers have opened new avenues for integrating AI-driven models in pharmaceutical pipelines. This synergy allows for a more rational and accelerated approach to identifying promising chemical scaffolds, optimizing biological activity, and tailoring drug properties to overcome clinical challenges such as resistance and adverse effects. The use of patient-derived organoids further adds clinical relevance by providing ex vivo models that recapitulate tumor heterogeneity and patient-specific responses, bridging the gap between preclinical findings and clinical outcomes.

Importantly, the cascade model devised combines classification and generative components to not only predict but also generate chemical entities with desired phenotypic profiles. This dual capability sets it apart from traditional predictive models limited by existing chemical space. By iteratively refining generated molecules based on predicted activity, the platform maximizes innovation potential, generating candidates that may otherwise remain unexplored. The subnanomolar potency of the identified tetrahydrocarbazoles speaks to the model’s efficacy in guiding molecular design toward high-affinity, biologically relevant compounds.

Furthermore, the click-activated prodrug strategy exemplifies cutting-edge advances in drug delivery technologies. Bioorthogonal chemistry, such as trans-cyclooctene (TCO) click reactions used here, enables spatiotemporal control over drug activation, offering a transformative approach to mitigate systemic toxicities common in chemotherapy. This method aligns well with precision medicine goals by allowing clinicians to target therapy more narrowly, potentially enhancing patient tolerance and improving therapeutic indices in oncologic treatment regimens.

The comprehensive approach detailed in this research serves as a blueprint for future efforts combining computational and experimental modalities. The confirmation of antitumor activity through rigorous wet-lab validation, including action against multidrug-resistant cancer cell models and patient-derived organoids, strengthens the translational relevance of the findings. As drug resistance remains one of the most formidable hurdles in effective cancer therapy, the identification of agents active against such resistant populations marks a significant milestone.

By upregulating p53 and engaging intrinsic apoptotic pathways, these tetrahydrocarbazole derivatives invoke a mechanism widely regarded as a cornerstone of tumor suppression. Given that many cancers harbor p53 mutations or dysfunctions, the capability of these compounds to modulate this pathway opens possibilities for combinatorial strategies alongside existing modalities targeting complementary oncogenic mechanisms. The detailed molecular characterization performed sets the stage for subsequent optimization and clinical development.

In conclusion, the advent of deep learning-powered drug discovery frameworks, exemplified by the identification and validation of tetrahydrocarbazole derivatives with broad-spectrum antitumor efficacy and click-activated prodrug capabilities, heralds a new era in precision oncology. This research not only enriches the pipeline of promising anticancer agents but also underscores the transformative impact of AI in accelerating and refining drug innovation. The integration of phenotypic screening, deep learning, and advanced drug delivery technologies forms a potent triad poised to confront the multifaceted challenges of cancer therapy in the coming decade.

Subject of Research: Deep learning-driven phenotypic drug discovery focused on broad-spectrum antitumor agents and click-activated targeted cancer therapy.

Article Title: Deep learning-based discovery of tetrahydrocarbazoles as broad-spectrum antitumor agents and click-activated strategy for targeted cancer therapy.

News Publication Date: Not specified.

Web References: DOI 10.1016/j.apsb.2025.10.005

Keywords: Deep learning, Phenotypic screening, Tetrahydrocarbazoles, Drug delivery, Click-activated prodrug, Antitumor, Drug discovery, p53

Among the awardees, Dr. Manu De Rycker from the University of Dundee has garnered the WH Pierce Global Impact in Microbiology Prize. Dr. De Rycker’s groundbreaking work in drug discovery focuses on kinetoplastid parasites, including those responsible for African sleeping sickness, visceral leishmaniasis, and Chagas disease. By developing sophisticated cell-based assays and screening cascades, his lab has enabled high-throughput screening methods with enhanced physiological relevance. This innovative approach has accelerated the identification and development of clinical candidates, most notably two for visceral leishmaniasis, and several advanced compounds targeting Chagas disease, in collaboration with pharmaceutical giant GlaxoSmithKline.

Professor Joana Falcao Salles of the University of Groningen was honored with the Basil Jarvis Food Security and Innovation Award for her seminal contributions to microbial community ecology, particularly in soil and host-associated microbiomes. Her integrative research merges ecological theory with computational and experimental methodologies to understand how microbial diversity underpins ecosystem resilience and suppresses disease, thereby advancing sustainable agricultural systems. A key highlight of her work rests on elucidating microbial invasions and plant genotype-driven enhancement of beneficial microbiome interactions, which collectively reduce reliance on chemical inputs, thus fostering environmentally responsible agriculture.

The John Snow Public Health Innovation Prize was awarded to Dr. José Luis Balcazar from the Catalan Institute for Water Research. Dr. Balcazar’s research is instrumental in unraveling the mechanisms by which antimicrobial resistance genes disseminate across environmental and clinical settings. His studies have illuminated the pivotal role of bacteriophages in horizontal gene transfer and resistance propagation. Moreover, his discovery of auxiliary metabolic genes within phages inhabiting polluted habitats opens promising avenues for bioremediation strategies, while simultaneously contributing critical insights to public health surveillance and water safety enhancement.

Professor Elaine Cloutman-Green, a Consultant Clinical Scientist at Great Ormond Street Hospital, received the Christiana Figueres Policy to Practice Award. Recognized for her decisive role in translating microbiological research into actionable healthcare policies, Professor Cloutman-Green’s career encapsulates innovation in infection prevention and control. Her pioneering PhD work dissected the environmental factors in healthcare-associated infections, culminating in rapid diagnostic tools and infection control methodologies that are currently implemented in hospitals worldwide to mitigate pathogen transmission and improve patient safety.

Advancing environmental conservation, Professor Thomas Crowther was distinguished with the Rachel Carson Environmental Conservation Excellence Award. A global biodiversity ecologist, Crowther’s research network, the Crowther Lab, investigates biodiversity’s influence on climate regulation and human wellbeing. Through innovative platforms like Restor.eco, founded in 2020, he facilitates widespread community-driven restoration efforts globally, aiming to rehabilitate soils and vegetation across millions of hectares. Crowther’s leadership extends to pivotal roles such as co-chairing the UN Decade on Ecosystem Restoration’s Advisory Board and being recognized by the World Economic Forum as a Young Global Leader for his biodiversity conservation efforts.

The Dorothy Jones Diversity & Inclusion Achievement Award acknowledged individuals and teams advancing equity within STEM fields. Max Fisher, recognized as the UK’s most influential disabled scientist for 2024, has been a tireless advocate of intersectionality and representation for disability and LGBTQIA+ communities within science. Their advocacy integrates lived experience with professional expertise in nanomedicine, leveraging roles such as a Senior Research Associate at ViaNautis Bio and affiliations with societies like The Science Council and the Royal Society of Biology. Fisher emphasizes the importance of role models for marginalized groups striving to navigate scientific careers.

Complementing this, the team award under the same category was conferred to the Microbes and Social Equity (MSE) Working Group. Dr. Sue Ishaq, representing the group, articulated the mission to interconnect microbiology with social equity disciplines, fostering an interdisciplinary approach that addresses inequities impacting microbial exposures and consequent health outcomes. MSE’s work bridges scientific research with policy and education, aiming to mitigate disparities linked to environmental and social determinants through evidence-based advocacy and practice, thereby promoting sustainability and equitable public health.

These awards by AMI not only celebrate individual and collective scientific excellence but also highlight the interdisciplinary and global nature of applied microbiology’s impact on health, agriculture, environment, and social justice. The honorees exemplify how cutting-edge research, collaborative innovation, and policy engagement converge to foster sustainable futures and responsive solutions to critical challenges faced worldwide.

The 2025 Horizon Awards demonstrate the breadth of applied microbiology in addressing complex issues such as neglected tropical diseases, antimicrobial resistance, sustainable agriculture, ecosystem restoration, and inclusion within scientific communities. The intersection of molecular innovation, ecological understanding, environmental science, and social equity underscores a robust, multifaceted approach to modern microbiological challenges.

By embracing a holistic vision of microbiology’s role in society, these awards reinforce the importance of fostering diverse voices and interdisciplinary collaboration. Applied Microbiology International, through these recognitions, continues to champion the advancement of science aimed at improving global health, food security, environmental sustainability, and social inclusion.

Scientists, policymakers, industry leaders, and advocates featured in the Horizon Awards serve not only as innovators but as visionaries propelling microbiology toward tangible, world-changing outcomes. Their cumulative work inspires ongoing commitment to research excellence, practical implementations, and advocacy that will shape the trajectory of microbiology and its contributions to humanity in the years to come.

With these announcements, AMI encourages the global microbiological community to continue pursuing transformative research and inclusive practices, emphasizing that the future of applied microbiology lies in its capacity to address urgent global imperatives through scientific rigor, collaboration, and equity.

Subject of Research: Applied microbiology with focus areas including drug discovery for parasitic diseases, microbial ecology in sustainable agriculture, antimicrobial resistance mechanisms, clinical infection control, biodiversity conservation, and diversity and inclusion in STEM.

Article Title: Applied Microbiology International Announces Horizon Awards 2025 Honoring Pioneers Transforming Global Challenges through Microbiology

News Publication Date: 2024

Web References:
– Applied Microbiology International: https://appliedmicrobiology.org/
– University of Dundee Drug Discovery Unit: https://drugdiscovery.dundee.ac.uk/
– Crowther Lab: https://crowtherlab.com/
– Restor.eco: https://restor.eco/

Keywords: Applied microbiology, drug discovery, kinetoplastid parasites, African sleeping sickness, visceral leishmaniasis, Chagas disease, microbial community ecology, soil microbiomes, antimicrobial resistance, bacteriophages, bioremediation, infection prevention, biodiversity conservation, ecosystem restoration, social equity, diversity and inclusion in STEM, microbial surveillance, sustainable agriculture, public health policy.

Benzimidazole derivatives have long been recognized for their diverse pharmacological profiles, which include antifungal, anti-inflammatory, and antiviral activities. Their structural versatility allows for significant modifications that can enhance bioactivity and selectivity. Xie et al. leverage this characteristic by synthesizing a library of benzimidazole derivatives, setting the stage for high-throughput screenings aimed at identifying candidates that can effectively disrupt the RSV fusion process. This approach epitomizes the intersection of synthetic chemistry and computational biology in modern drug discovery.

The QSAR methodology employed in this study serves as a powerful predictive tool to establish relationships between chemical structure and biological activity. By analyzing various physicochemical properties of the benzimidazole derivatives, the researchers were able to construct predictive models that offer insights into how specific structural features correlate with antiviral efficacy. This data-driven approach minimizes experimental bottlenecks and accelerates the identification of lead compounds.

Molecular docking simulations play a crucial role in the computational assessment of binding affinities between the synthesized compounds and the RSV fusion protein. The study harnesses advanced docking algorithms to visualize and predict the mode of interaction between the antiviral agents and their target protein. These insights not only bolster the understanding of the binding interactions but also guide the design of more potent inhibitors, an essential step in the drug development pipeline.

One of the study’s most notable features is its comprehensive ADMET profiling, which evaluates the pharmacokinetic properties of the candidate compounds. Assessing the absorption, distribution, metabolism, excretion, and toxicity of these molecules is vital to ensuring their viability as therapeutic agents. Potential inhibitors that show promising antiviral activity must also possess favorable ADMET characteristics to predict their success in clinical settings.

Through meticulous experimentation and analysis, Xie et al. have delineated several benzimidazole derivatives that exhibit significant inhibitory activity against RSV. These findings represent a substantial step forward in antiviral therapeutics, particularly given the limited options currently available for treating RSV infections. The study underscores the potential for repurposing existing chemical frameworks, like benzimidazoles, to expedite the discovery process for new antiviral agents.

Importantly, the research community recognizes the urgency for novel RSV therapeutics due to rising incidence rates and the impact of COVID-19 on healthcare systems worldwide. In such a context, the findings of Xie et al. not only answer a critical need but also open avenues for subsequent research that could lead to effective treatments for both RSV and other respiratory viruses.

The rigorous scientific methodology used in this study adds credibility to its conclusions. By intertwining experimental results with computational predictions, the researchers provide a robust framework for the development of antiviral drugs. This integrative approach not only enhances the precision of drug design but also paves the way for future innovations in antiviral research.

The study also highlights the necessity for collaborative efforts among various scientific disciplines. Combining expertise from medicinal chemistry, pharmacology, and computational biology leads to a more holistic understanding of drug action and resistance mechanisms. Such interdisciplinary collaboration is essential in addressing complex challenges presented by viral infections, especially in a rapidly evolving landscape.

A notable aspect of the research is its implication for global health; as RSV remains a leading cause of morbidity and mortality, effective antiviral therapies could have a profound impact. Ensuring that these findings translate to practical treatments will rely on continuous investment in both research and development, as well as successful navigation of the regulatory landscape.

Additionally, the study serves as a reminder of the importance of innovation in drug design. Traditional methods of drug discovery can be time-consuming and costly, but the synergy of QSAR modeling and molecular docking offers a pathway to streamline the process. By reducing dependence on trial-and-error, researchers can focus their resources on the most promising candidates, thus optimizing the chances of success in clinical trials.

In summary, the work of Xie et al. represents a beacon of hope in the search for effective RSV treatments. By exploring the potential of benzimidazole derivatives through a comprehensive methodology that includes QSAR, molecular docking, and ADMET evaluations, the authors set the stage for a new era of antiviral drug development. As public health challenges persist, studies such as this one are crucial in the quest to mitigate the burden of viral infections and improve patient outcomes.

The implications of this research extend beyond the immediate target of RSV. The methodologies employed could be adapted to explore other viral pathogens, creating a flexible framework for future antiviral drug design. As the scientific community rallies to address infectious disease threats, the findings of this study could inspire a new wave of antiviral discovery focused on structural analogs that effectively target various viral machineries.

In light of the ongoing challenges presented by respiratory viruses, the predictive power of computational methodologies alongside traditional experimental approaches can expedite the translation of academic research into clinical applications. As researchers continue to unravel the complexities of viral pathology, it is critical that studies like the one conducted by Xie et al. are supported and amplified, facilitating a concerted response to emerging viral threats on a global scale.

Amidst the ongoing discourse on the strategies for combating respiratory infections, Xie et al.’s work stands out as a significant contribution. As new methodologies evolve and the scientific terrain shifts, the continuous exploration of novel compounds—rooted in the principles of medicinal chemistry and informed by computational insights—will be integral to shaping future therapies that can effectively target viral infections.

Subject of Research: Discovery of potential RSV fusion protein inhibitors from benzimidazole derivatives using QSAR, molecular docking, and ADMET evaluation methods.

Article Title: Discovery of potential RSV fusion protein inhibitors from benzimidazole derivatives using QSAR, molecular docking, and ADMET evaluation methods.

Article References:

Xie, Y., Jia, R., Fan, T. et al. Discovery of potential RSV fusion protein inhibitors from benzimidazole derivatives using QSAR, molecular docking, and ADMET evaluation methods.
Mol Divers (2025). https://doi.org/10.1007/s11030-025-11360-x

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11030-025-11360-x

Keywords: RSV, antiviral, benzimidazole derivatives, QSAR, molecular docking, ADMET.

This pioneering research, conducted by a team led by co-first authors Seong Guk Park, PhD, and Elizabeth Kellogg, PhD, from the Department of Structural Biology at St. Jude, was recently published in the journal Nucleic Acids Research. Their method stands out as it enables the rapid optimization of promising CAST candidates, ultimately uncovering essential mechanistic insights that will inform further engineering endeavors. This advancement marks a significant stride in addressing the limitations that have traditionally encumbered the adaptation of CASTs for human applications.

CASTs, which were discovered in 2017, provide a one-step solution for genome editing by integrating large DNA sequences at designated locations in the genome, guided by RNA sequences. Their specificity has been well-documented within bacterial systems, their original hosts; however, they have been less effective in human cells. Consequently, the research team’s objective concentrated on enhancing these natural systems to increase their applicability in human and other eukaryotic organisms.

Corresponding author Elizabeth Kellogg emphasized the necessity of a scalable method to evaluate engineered CASTs’ strengths and weaknesses. Prior to the development of this high-throughput screening approach, the understanding of CASTs was limited to measuring overall activity, without thoroughly assessing the specificity of their DNA integrations. The researchers aimed to fill this void in knowledge by designing a method that could simultaneously measure both aspects.

Utilizing this new screening technique, the team focused on a specific subtype known as the V-K CAST. This variant is particularly advantageous due to its relatively simpler structure compared to other CASTs, making it ideal for experimentation. By altering the proteins of the V-K CAST, the researchers were able to explore a vast range of mutations, evaluating thousands of variants in a single experiment. This broad approach allowed them to delve deep into the mutational landscape of the CAST system, which was previously unexplored territory.

Co-first author Seong Guk Park elaborated on the motivation behind this study, revealing their intention to test all possible single mutations to identify those that could enhance CAST efficiency. Their comprehensive strategy, which did not target any specific regions of the CAST, was instrumental in uncovering beneficial mutations. The team’s exhaustive exploration yielded insights that could significantly impact future research in genetic editing.

Following the application of the V-K CAST mutational screening, the researchers discovered that certain combinations of the most promising mutations could have additive benefits. Specifically, they observed a fivefold increase in activity attributable to just a few modifications. Remarkably, this increase in activity did not come at the expense of specificity—an achievement that previous engineering strategies had been unable to accomplish. This kind of advancement exemplifies the potential of the team’s high-throughput screening method to revolutionize genetic engineering approaches.

With this pressing need for specificity and efficiency in genetic editing, Kellogg and her team are encouraged by the groundbreaking possibilities brought forth by this research. The intricate nature of the natural CAST systems presents hurdles, but the screening approach enables more aspirations in the design of proteins with enhanced capabilities. The researchers are optimistic about future developments resulting from this work, believing that it could lead to more minimal systems conducive for clinical applications.

The study not only underscores the steps taken by St. Jude’s researchers to optimize CASTs, but it also highlights the collaborative efforts undertaken by a diverse team of experts. The contributions of Jung-Un Park from the University of California, Berkeley, along with colleagues Esteban Dodero-Rojas, John Bryant Jr., and Geetha Sankaranarayanan, add depth to the findings and reflect the integrative nature of modern scientific research.

Funded by prominent organizations such as the National Institutes of Health, the Pew Charitable Trusts, and various other institutions, this study exemplifies a commitment to advancing genetic research. The financial backing underscores the importance of this research in providing innovative solutions to pressing health concerns, emphasizing the collaboration between research institutions and funding bodies in the pursuit of transformative scientific knowledge.

As research continues in this dynamic area, Kellogg and her colleagues will remain steadfast in their endeavors to refine CAST designs further. The high-throughput screen they’ve developed will facilitate ambitious efforts to progress in protein design. While the complexities inherent to natural systems are extensive, the newfound capabilities will undoubtedly catalyze advancements in genetic engineering, potentially revolutionizing therapies for genetic disorders and beyond.

The implications of this research stretch far beyond the laboratory. As these engineered CASTs find greater utility in clinical settings, they could pave the way for new therapeutic approaches, enabling precise modifications that enhance human health. With ongoing research and development, the future of genetic editing appears promising, with potential breakthroughs lying just ahead.

The journey of refining CRISPR-associated transposons is a testament to the synergy of scientific exploration and technological advancement. By tapping into the nuances of genetic editing, researchers are positioned to tackle some of humanity’s most enduring challenges, ultimately contributing to a healthier, more informed world.

In conclusion, this research not only leads to practical applications in genetic engineering but also exemplifies the broader potential of interdisciplinary cooperation in science. By embracing methodologies that enhance specificity and efficiency, researchers are forging new paths in the quest for medical breakthroughs, ensuring that the work at St. Jude Children’s Research Hospital resonates for generations.

Subject of Research: CRISPR-associated transposons (CASTs)
Article Title: Screening Approach Enhances CRISPR Genome-Editing Efficiency
News Publication Date: September 23, 2025
Web References: St. Jude Children’s Research Hospital, Nucleic Acids Research
References: National Institutes of Health, Pew Charitable Trusts, Cystic Fibrosis Foundation, Jane Coffin Childs Memorial Fund, Korea Health Industry Development Institute, National Cancer Institute, American Lebanese Syrian Associated Charities
Image Credits: St. Jude Children’s Research Hospital

Keywords

CRISPR, gene editing, genome engineering, CASTs, biomedical applications, specificity, efficiency, high-throughput screening, protein design, genetic disorders.

Cell Painting represents a cutting-edge high-throughput microscopy method that labels multiple cellular components with fluorescent dyes, capturing thousands of images that reveal subtle morphological changes in cells exposed to diverse compounds. According to the study’s corresponding author, Dr. Michael Mancini, professor of molecular and cellular biology and director of Baylor’s Integrated Microscopy Core, this technology allows researchers to observe cellular responses at an unprecedented resolution. By applying custom image analysis pipelines, the team quantified dynamic alterations in cellular structures, providing a detailed phenotypic fingerprint of how each flavonoid interacts with cancer cells.

One of the major challenges of such high-content screening approaches is the sheer volume of data generated. Each Cell Painting experiment can produce over 57,000 confocal microscopy images per plate, a dataset too vast for manual analysis and often requiring substantial computational resources. To overcome this bottleneck, Dr. Mancini’s lab developed SPACe (Swift Phenotypic Analysis of Cells), a novel computational tool capable of individually assessing thousands of cells across numerous experimental plates. Impressively, SPACe can operate efficiently on standard desktop computers, making large-scale drug screening accessible to laboratories regardless of their computational infrastructure.

Applying this powerful methodology, the research team analyzed a library of 244 flavonoid compounds against three widely studied bladder cancer cell lines. Their findings revealed six flavonoids exhibiting significant cytotoxicity, effectively eliminating malignant cells without harming normal bladder cells. Among these were flavopiridol and rotenone, compounds already known for their toxic effects, thereby validating the accuracy of their screening approach. Intriguingly, some flavonoids acted through inducing DNA damage in the cancer cells, while others disrupted mitochondrial function—a critical pathway for cellular energy production—signaling multiple therapeutic mechanisms within this compound class.

Beyond traditional two-dimensional cultures, the study advanced towards more physiologically relevant models, including 3D spheroids and chorioallantoic membrane (CAM) systems, which better mimic tumor architecture and microenvironment. Three of the toxic flavonoids were found to reduce tumor growth in these 3D culture systems as well, reinforcing their potential clinical utility. Significantly, these compounds did not inhibit growth in normal bladder cells, suggesting a degree of cancer cell specificity that could minimize harmful side effects in future therapies.

Among the standout compounds is xanthohumol, a flavonoid derived from hops and found in certain types of beer. The study uncovered that xanthohumol-induced cell death was tightly linked to a reduction in lipid metabolism, particularly a pronounced decrease in the number of lipid droplets within cancer cells. Lipid droplets serve not only as energy stores but also as mediators of cellular signaling and stress responses, marking a novel mechanism of flavonoid-induced cytotoxicity. The possible correlation between xanthohumol consumption and bladder cancer incidence presents a fascinating avenue for epidemiological exploration.

The implications of this research extend well beyond the identification of promising flavonoids. By harnessing the combined power of Cell Painting and SPACe, the Baylor team demonstrated a scalable and precise platform for phenotypic drug discovery that captures the complex heterogeneity of cancer cell populations. This approach allows scientists to classify compounds based on their distinct cellular impact profiles, accelerating the next generation of targeted oncology therapeutics.

Flavonoids themselves are ubiquitously present in fruits, vegetables, and beverages, which raises intriguing possibilities about natural dietary components contributing to cancer prevention or therapy. However, the translation of these in vitro findings to clinical applications requires rigorous validation, including assessment of flavonoid safety, bioavailability, and efficacy in living organisms. The authors emphasize ongoing plans to test these compounds in animal models bearing human bladder tumors and eventually move towards clinical trials to evaluate their therapeutic potential in patients.

The study was a collaborative effort including researchers Jessica Oceguera, Alejandra Rivera Tostado, Christopher D. Candler, Elina Mosa, Kazem Safari, and Maureen G. Mancini. These contributors brought expertise spanning molecular biology, microscopy, and computational analysis, while their institutional support included Baylor College of Medicine and the Texas A&M University’s GCC Center for Advanced Microscopy and Image Informatics.

Funding for this research was provided by multiple prestigious grants, notably from the Cancer Prevention and Research Institute of Texas (CPRIT), the GCC Center for Precision Environmental Health, and the Dan L Duncan Comprehensive Cancer Center. These support mechanisms highlight the critical investment required to facilitate transformative cancer research employing cutting-edge technologies.

As bladder cancer continues to rank as the fifth most common cancer in the United States, causing over 16,000 deaths annually, the need for innovative treatments is urgent. Current clinical practices, while effective at tumor removal and relapse control, often struggle with residual disease that can metastasize. The identification of flavonoids exhibiting selective cytotoxicity against bladder cancer cells offers a hopeful new avenue for improving patient outcomes through less toxic and potentially more effective therapies.

In summary, the marriage of phenotypic screening technologies with natural product libraries exemplified in this study sets a new paradigm in oncology drug discovery. Flavonoid compounds such as xanthohumol exhibit unique cellular interactions that disrupt cancer metabolism and genomic integrity, positioning them as attractive candidates for future therapeutics. This exciting research not only generates a wealth of actionable knowledge but also opens the door to safer, more accessible, and finely tuned cancer treatments, potentially redefining the therapeutic landscape for bladder cancer.

Subject of Research: Human tissue samples

Article Title: A phenotypic screen identifies xanthohumol and other flavonoids as killers of bladder cancer

News Publication Date: 22-Apr-2025

Web References:

• Pharmacological Research – Natural Products Journal
• DOI: 10.1016/j.prenap.2025.100236

Keywords: Human health, Imaging, Microscopy, Organismal biology, Oncology